DUBLIN–(BUSINESS WIRE)–The “Global
Addison’s Disease Therapeutics Market 2019-2023” report has
been added to ResearchAndMarkets.com’s offering.
The Addison’s disease therapeutics market will register a CAGR of nearly
4% by 2023.
The favorable reimbursement scenario is one of the key factors expected
to trigger the market growth during the forecast period. Reimbursement
is quite essential for ensuring wider patient access to the Internet.
Insurers are increasingly providing complete reimbursement for most of
the drugs indicated for the treatment of adrenal insufficiency.
In addition, governments and healthcare agencies are further investing a
huge amount of money in improving national or regional health. As a
result, the supporting reimbursement policies are expected to contribute
significantly to the Addison’s disease therapeutics market growth during
the forecast period.
Market Overview
Special drug designations
Special drug designations promote vendors to come up with better drugs
in the market, which extends the product offerings to patients and their
adherence to therapeutic alternatives. This, in turn, drives the market
growth.
Adverse effects associated with available drugs
The drugs that are available in the market include glucocorticoids and
mineralocorticoids, which are associated with harmful side effects.
These side effects exert a negative impact on the quality of life of the
patients and reduce their willingness to continue treatment with the
drugs.
Competitive Landscape
The market appears to be moderately fragmented with the presence of
several market players. Various companies are focusing on investing in
R&D of the medicines for curing rare and orphan diseases, including
Addison’s disease, along with the chronic illnesses such as central
nervous system (CNS) disorders, and cancer.
This market research report will help clients identify new growth
opportunities and design unique growth strategies by providing a
comprehensive analysis of the market’s competitive landscape and
offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Oral drugs – Market size and forecast 2018-2023
- Parenteral drugs – Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/z3xmi9
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs